With a median progression-free survival nearing four years in ROS1 lung cancer, Nuvation Bio’s breakthrough therapy signals a turning point for precision oncology - validating Dr. David Hung’s patient-first vision.
September’s FDA approvals signaled shifting rules in biopharma - faster launches, smarter formulations, and bold plays from rising innovators and the familiar giants.
Backed by $70 million in Series A funding, Excellergy emerges from stealth with a mission to lead a new era in immunology - targeting the full IgE pathway to redefine how allergic diseases are treated.
“Fifteen to twenty years ago, a woman under 35 had a 20% chance of live birth per IVF cycle. At Kindbody, today, it’s greater than 50%,” David Stern credits lab innovation and AI for rewriting fertility’s odds.
“After just one single infusion, about a third of patients remained in remission for five years. Some physicians even called it a functional cure,” Ying Huang underlines why CARVYKTI is reshaping expectations in oncology.
“Preventative care spending fell from 14.1% to just 5.2% of Government healthcare spending.” Ben Phillips warns that welfare reforms could widen existing health gaps.
Anis Fahandej-Sadi breaks down the big problems with current incentive structures
"Some companies can’t even finish clinical trials because they can’t get enough material. It all comes down to the supply chain,” Thomas Eiden underscores why secure isotope access is critical for next-generation cancer treatment.
All the details on when the 44th annual J.P. Morgan Healthcare Conference takes place!
"Almost a third of over-65s will fall each year", but could nGVS represent a discreet tool against imbalance?
To live in the grey zone of sub-clinical pathology is to be unwell enough to hurt, but not enough to be heard.
First-generation medical students carry two textbooks - one devoted to anatomy, the other towards cultivating resilience.
Trillions of microbes inside us are not mere bystanders, but quiet architects of our moods.
"These projects are more than acts of goodwill," China's Health Silk Road is as much about soft power as it is about medicine.
“Pain is treated like a badge of honor" in medicine, but the cost is a workforce breaking under invisible pressure.
"AI has already been shown to be just as, if not more, accurate than dermatologists," Dr. Alexander Green explains, as DERM proves 99.8% effective at ruling out cancer.
